Back to MDLN Overview
NMS · Valuation Lab
MDLN
Medline Inc.
Last$36.66
Market cap65.3B
EV/EBITDA17.3x
Intrinsic value
$140.16
MoS +73.8% · Undervalued
Assuming 15.0% FCF margin and 10.7% Y1–5 growth.
Upside to price
EV (DCF)128.9B
Terminal share64%
Expected IV$149.24
Probability weights
Projected free cash flows
Stage FCF path with present values · terminal 64% of EV
PV of stage FCFs46.6B
PV of terminal value82.3B
Enterprise value128.9B
Net cash / (debt)-10.4B
Equity value118.5B
Intrinsic value / share$140.16
| Year | Revenue | FCF | PV | DF |
|---|---|---|---|---|
| Y1 | 32.3B | 4.8B | 4.5B | 92.6% |
| Y2 | 35.7B | 5.4B | 4.6B | 85.8% |
| Y3 | 39.5B | 5.9B | 4.7B | 79.4% |
| Y4 | 43.8B | 6.6B | 4.8B | 73.6% |
| Y5 | 48.4B | 7.3B | 5B | 68.2% |
| Y6 | 51.1B | 7.7B | 4.8B | 63.1% |
| Y7 | 53.8B | 8.1B | 4.7B | 58.5% |
| Y8 | 56.7B | 8.5B | 4.6B | 54.1% |
| Y9 | 59.8B | 9B | 4.5B | 50.2% |
| Y10 | 63B | 9.5B | 4.4B | 46.4% |
| Terminal | — | — | 82.3B | — |
Educational DCF model only — not financial advice. Terminal value and assumptions dominate results; verify filings and run your own diligence.